Your browser doesn't support javascript.
loading
Human Leukocyte Antigen Genotype as a Marker of Multiple Sclerosis Prognosis.
Lysandropoulos, Andreas P; Perrotta, Gaetano; Billiet, Thibo; Ribbens, Annemie; Du Pasquier, Renaud; Pot Kreis, Caroline; Maggi, Pietro; Théaudin, Marie.
Afiliación
  • Lysandropoulos AP; Department of Neurology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Perrotta G; Department of Neurology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Billiet T; Icometrix, Leuven, Belgium.
  • Ribbens A; Icometrix, Leuven, Belgium.
  • Du Pasquier R; Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Pot Kreis C; Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Maggi P; Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Théaudin M; Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Can J Neurol Sci ; 47(2): 189-196, 2020 03.
Article en En | MEDLINE | ID: mdl-31787121
OBJECTIVE: In a previous pilot monocentric study, we investigated the relation between human leukocyte antigen (HLA) genotype and multiple sclerosis (MS) disease progression over 2 years. HLA-A*02 allele was correlated with better outcomes, whereas HLA-B*07 and HLA-B*44 were correlated with worse outcomes. The objective of this extension study was to further investigate the possible association of HLA genotype with disease status and progression in MS as measured by sensitive and complex clinical and imaging parameters. METHODS: Hundred and forty-six MS patients underwent HLA typing. Over a 4-year period of follow-up, we performed three clinical and magnetic resonance imaging (MRI) assessments per patient, which respectively included Expanded Disability Status Scale, Multiple Sclerosis Severity Scale, Timed-25-Foot-Walk, 9-Hole Peg Test, Symbol Digit Modalities Test, Brief Visual Memory Test, California Verbal Learning Test-II, and whole-brain atrophy, fluid-attenuated inversion recovery (FLAIR) lesion volume change and number of new FLAIR lesions using icobrain. We then compared the clinical and MRI outcomes between predefined HLA patient groups. RESULTS: Results of this larger study with a longer follow-up are in line with what we have previously shown. HLA-A*02 allele is associated with potentially better MS outcomes, whereas HLA-B*07, HLA-B*44, HLA-B*08, and HLA-DQB1*06 with a potential negative effect. Results for HLA-DRB1*15 are inconclusive. CONCLUSION: In the era of MS treatment abundance, HLA genotype might serve as an early biomarker for MS outcomes to inform individualized treatment decisions.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos de Histocompatibilidad Clase I / Esclerosis Múltiple Crónica Progresiva / Esclerosis Múltiple Recurrente-Remitente / Cadenas beta de HLA-DQ Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Can J Neurol Sci Año: 2020 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos de Histocompatibilidad Clase I / Esclerosis Múltiple Crónica Progresiva / Esclerosis Múltiple Recurrente-Remitente / Cadenas beta de HLA-DQ Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Can J Neurol Sci Año: 2020 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Reino Unido